ERCC1-specific immunostaining in non-small-cell lung cancer.

No abstract is available for this paper.

• Publication year

  2007

• Venue

  New England Journal of Medicine

• Publication date

  2007-10-11

• Fields of study

  Medicine

• Identifiers
  DOI 10.1056/NEJMC072007PMID 17928611
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• ERCC1 and non-small-cell lung cancer.

  2007cited by this paper
• DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer.

  2007cited by this paper
• ERCC1 and non-small-cell lung cancer [8]

  2007cited by this paper
• DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy.

  2006cited by this paper
• Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin.

  2005cited by this paper
• Functional and physical interactions between ERCC1 and MSH2 complexes for resistance to cis-diamminedichloroplatinum(II) in mammalian cells.

  2004cited by this paper

• Inhibition of nucleotide excision repair proteins associated with cancer chemotherapy.

  2025cites this paper
• Development of Clinical Prediction Score for Chemotherapy Response in Advanced Non-Small Cell Lung Cancer Patients

  2023cites this paper
• Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma

  2018cites this paper
• ERCC1 as Predictor of Platinum Benefit in Non-Small-Cell Lung Cancer.

  2017cites this paper
• Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET).

  2017cites this paper
• Adjuvant immunotherapy in resected early non-small cell lung cancer-battle lost, hopefully not the war!

  2016cites this paper
• Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2016cites this paper
• Genetic Polymorphisms and Cisplatin- Related Nephrotoxicity

  2015cites this paper
• Clinical evaluation of postoperative chemotherapy based on genetic testing in patients with stage IIIA non‐small cell lung cancer

  2015cites this paper
• Personalisation of therapy in advanced colorectal cancer

  2015cites this paper
• Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum–paclitaxel chemotherapy

  2014cites this paper
• Expression of DNA-repair proteins and their significance in pancreatic cancer and non-cancerous pancreatic tissues of Sprague–Dawley rats

  2014cites this paper
• ERCC1 expression correlated with EGFR and clinicopathological variables in patients with non-small cell lung cancer. An immunocytochemical study on fine-needle aspiration biopsies samples.

  2014cites this paper
• Prognostic significance of PIK3CA and SOX2 in Asian patients with lung squamous cell carcinoma

  2014cites this paper
• First-Line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients

  2014cites this paper
• Prognostic value of ERCC1 mRNA expression in non-small cell lung cancer, breast cancer, and gastric cancer in patients from Southern China.

  2014cites this paper
• RCC1 expression correlated with EGFR and linicopathological variables in patients with non-small ell lung cancer. An immunocytochemical study on ne-needle aspiration biopsies samples

  2014cites this paper
• Commercial laboratory testing of excision repair cross-complementation group 1 expression in non-small cell lung cancer.

  2014cites this paper
• In vitro assessment of Macleaya cordata crude extract bioactivity and anticancer properties in normal and cancerous human lung cells.

  2013cites this paper
• ERCC1 isoform expression and DNA repair in non-small-cell lung cancer.

  2013cites this paper
• Association between ERCC1 and XPA expression and polymorphisms and the response to cisplatin in testicular germ cell tumours

  2013cites this paper
• TUBB3/STMN1基因表达与非小细胞肺癌EGFR通路的相关性

  2013cites this paper
• ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma.

  2013cites this paper
• Customizing chemotherapy in thoracic malignancies based on ERCC1 expression

  2013cites this paper
• Synthetic lethality and functional study of DNA repair defects in ERCC1-deficient non-small-cell lung cancer

  2013influential citation
• ERCC1 and RRM1: ready for prime time?

  2013cites this paper
• Metformin Induces Cytotoxicity by Down‐Regulating Thymidine Phosphorylase and Excision Repair Cross‐Complementation 1 Expression in Non‐Small Cell Lung Cancer Cells

  2013cites this paper
• Location and Biomarker Characterization of Circulating Tumor Cells

  2012cites this paper
• Linking The Multiple Functions of XPF-ERCC1 Endonuclease in DNA Repair to Health Outcomes: Cancer and Aging

  2012cites this paper
• Loss-of-function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer

  2012cites this paper
• Cancer genomics: technology, discovery, and translation.

  2012cites this paper
• Role of hormone receptor expression in patients with advanced-stage lung cancer treated with chemotherapy.

  2012cites this paper
• Impact of ERCC1 expression on treatment outcome in small-cell lung cancer patients treated with platinum-based chemotherapy.

  2012cites this paper
• Developments in the treatment of early NSCLC: when to use chemotherapy.

  2012cites this paper
• RRM1 and ERCC1 expression in peripheral blood versus tumor tissue in gemcitabine/carboplatin-treated advanced non-small cell lung cancer

  2012cites this paper
• The potential of exploiting DNA-repair defects for optimizing lung cancer treatment

  2012cites this paper
• Biomarker-based selection of therapy for colorectal cancer.

  2011cites this paper
• Automated ERCC1 Immunohistochemistry in Non-small Cell Lung Cancer: Comparison of anti-ERCC1 Antibodies 8F1, D-10, and FL-297

  2011cites this paper
• ERCC1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy.

  2011cites this paper
• ERCC 1 influence on the incidence of brain metastases in patients with non-squamous NSCLC treated with adjuvant cisplatin-based chemotherapy

  2011cites this paper
• Automated ERCC1 immunochemistry on hybrid cytology/tissue microarray of malignant effusions: evaluation of antibodies 8F1 and D-10

  2011cites this paper
• Biomarker update for breast, colorectal and non-small cell lung cancer.

  2010cites this paper
• ERCC1-XPF nuclease: Roles in the repair of DNA interstrand crosslinks and chemotherapy resistance

  2010cites this paper
• Personalized medicine for non-small-cell lung cancer

  2010cites this paper
• Low ERCC1 mRNA and protein expression are associated with worse survival in cervical cancer patients treated with radiation alone.

  2010cites this paper
• MutS Homologue 2 and the Long-term Benefit of Adjuvant Chemotherapy in Lung Cancer

  2010cites this paper
• ERCC1 Expression Analysis to Guide Therapy in Non-Small Cell Lung Cancer

  2010cites this paper
• Biomarker-based prediction of response to therapy for colorectal cancer: current perspective.

  2010cites this paper
• ERCC1: impact in multimodality treatment of upper gastrointestinal cancer.

  2010cites this paper
• Reply to L.C. Panasci and D.S.-W. Tan et al

  2010cites this paper
• Truth about ERCC1 in lung cancer.

  2010cites this paper
• The Texas Advance Directives Act--is it a good model?

  2009cites this paper
• Immunodetection of DNA repair endonuclease ERCC1-XPF in human tissue.

  2009cites this paper
• The XPA-binding domain of ERCC1 Is Required for Nucleotide Excision Repair but Not Other DNA Repair Pathways*

  2009cites this paper
• Expression of excision repair cross complementing group 1 and prognosis in adrenocortical carcinoma patients treated with platinum-based chemotherapy.

  2009cites this paper
• FLEX data, KRAS and ERCC1 testing in oncology.

  2008cites this paper